Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Drug Repurposing for Japanese Encephalitis Virus Infection by Systems Biology Methods

Version 1 : Received: 19 November 2018 / Approved: 20 November 2018 / Online: 20 November 2018 (04:54:48 CET)

A peer-reviewed article of this Preprint also exists.

Lv, B.-M.; Tong, X.-Y.; Quan, Y.; Liu, M.-Y.; Zhang, Q.-Y.; Song, Y.-F.; Zhang, H.-Y. Drug Repurposing for Japanese Encephalitis Virus Infection by Systems Biology Methods. Molecules 2018, 23, 3346. Lv, B.-M.; Tong, X.-Y.; Quan, Y.; Liu, M.-Y.; Zhang, Q.-Y.; Song, Y.-F.; Zhang, H.-Y. Drug Repurposing for Japanese Encephalitis Virus Infection by Systems Biology Methods. Molecules 2018, 23, 3346.

Abstract

Japanese encephalitis is a zoonotic disease caused by Japanese encephalitis virus (JEV). It is mainly epidemic in Asia with an estimated 69,000 cases occurring per year. However, no approved agents are available for the treatment of JEV infection, and existing vaccines cannot resist various types of JEV strains. Drug repurposing is a new concept for finding new indication of existing drugs, and recently, it has been used to discover new antiviral agents. Identifying host proteins involved in the progress of JEV infection and using these proteins as targets are the center of drug repurposing for JEV infection. In this study, based on the gene expression data of JEV infection and the phenome-wide association study (PheWAS) data, we identified 286 genes participating in the progress of JEV infection using the systems biology methods. The enrichment analysis of these genes suggested that the genes identified by our methods were predominantly related to viral infection pathways and immune response-related pathways. We found that bortezomib which can target these genes may have potential effect on the treatment of JEV infection. Subsequently, we evaluated the antiviral activity of bortezomib using the JEV-infected mice model. The results showed that bortezomib can lower JEV-induced lethality in mice, alleviate suffering in JEV-infected mice and reduce the damage in brains caused by JEV infection. This work provides a new method for the development of antiviral agents.

Keywords

Japanese encephalitis virus; drug repurposing; systems biology; antiviral agents

Subject

Biology and Life Sciences, Neuroscience and Neurology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.